AI Summary

Scientists at King's College London reported that an experimental drug called KCL‑286, originally created for spinal‑cord injuries, showed promise in a mouse model of Alzheimer’s disease. The compound appeared to repair damaged DNA, lower brain inflammation, and influence other biological changes linked to the condition. Researchers highlighted that this multi‑target strategy differs from therapies that mainly address toxic protein buildup, potentially acting earlier in disease progression. The findings suggest a new avenue for tackling several harmful processes of Alzheimer’s simultaneously.

AI summaries can be wrong sometimes—always verify important details using the source article.